Last reviewed · How we verify
ATB-1012
ATB-1012 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.
At a glance
| Generic name | ATB-1012 |
|---|---|
| Sponsor | Autotelicbio |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Based on Autotelicbio's platform, ATB-1012 likely works through a mechanism that enhances or restores immune tolerance pathways, potentially through regulatory T cell induction or similar immunomodulatory mechanisms. The exact molecular target and detailed mechanism remain proprietary and not fully disclosed in public literature.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 (PHASE1)
- Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes (PHASE3)
- Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATB-1012 CI brief — competitive landscape report
- ATB-1012 updates RSS · CI watch RSS
- Autotelicbio portfolio CI